HASEGAWA Koki

写真a

Title

Professor

Research Fields, Keywords

Radiopharmaceutical Chemistry, Histochemistry

Mail Address

E-mail address

Current Affiliation Organization 【 display / non-display

  • Duty ,  School of Health Sciences ,  Depertment of Medical Radiology Technology ,  Professor

  • Concurrently ,  Fukushima Global Medical Science Center ,  Advanced Clinical Research Center ,  Professor

  • Concurrently ,  Hospital ,  Medical Imaging Center ,  Professor

Graduating School 【 display / non-display

  • Himeji Institute of Technology ,  Faculty of Engineering ,  Graduated ,  1997.03

  • Osaka University ,  Faculty of Dentistry ,  Graduated ,  2008.03

Career 【 display / non-display

  • 2002.10
    -
    2003.09

    Institute for Protein Research, Osaka University, Researcher

  • 2008.04
    -
    2012.04

    RIKEN, Researcher

  • 2012.05
    -
    2015.09

    Pathology and experimental medicine, Kumamoto University, Assistant professor

  • 2015.10
    -
    2021.03

    Center for Instrumental Analysis , Kyoto Pharmaceutical University, Associate professor

  • 2021.04
    -
    Now

    School of Health Sciences, Fukushima Medical University

Academic Society Affiliations 【 display / non-display

  • 1997.04
    -
    Now

    The Japanese Peptide Society ,  JAPAN

  • 2008.04
    -
    Now

    THE JAPANESE SOCIETY OF NUCLEAR MEDICINE ,  JAPAN

  • 2008.04
    -
    Now

    THE PHARMACEUTICAL SOCIETY OF JAPAN ,  JAPAN

  • 2013.04
    -
    Now

    JAPAN SOCIETY OF HISTOCHEMISTRY AND CYTOCHEMISTRY ,  JAPAN

  • 2013.04
    -
    Now

    THE JAPANESE SOCIETY OF PATHOLOGY ,  JAPAN

Field of expertise (Grants-in-aid for Scientific Research classification) 【 display / non-display

  • Radiation science

  • Human pathology

Qualification acquired 【 display / non-display

  • Dentist ,  2008.04

  • Hazardous Material Handler (first kind) ,  2015.03

 

Papers 【 display / non-display

  • アルファ線核医学治療のための薬剤開発の考察(その6) 標的分子・創薬化学の重要性(前編)

    矢野 恒夫, 長谷川 功紀, 石井 明子, 渡部 直史, 巽 光朗, 角永 悠一郎, 樺山 一哉, 深瀬 浩一, 米倉 義晴, 平林 容子, 佐藤 達彦, 藤井 博史

    PHARM TECH JAPAN ,  37 (11) 1921 - 1930 ,  2021.08

    Multiple Authorship ,  ISBN: 0910-4739

  • アルファ線核医学治療のための薬剤開発の考察(その5) IAEA Technical Meeting報告 α線核種並びにTAT薬剤の最新動向

    矢野 恒夫, 長谷川 功紀, 山村 朝雄, 渡部 直史, 巽 光朗, 佐藤 達彦, 角永 悠一郎, 樺山 一哉, 深瀬 浩一, 平林 容子, 藤井 博史, 米倉 義晴

    医薬品医療機器レギュラトリーサイエンス ,  52 (2) 85 - 106 ,  2021.02

    Multiple Authorship ,  ISBN: 1884-6076

  • Facile synthesis of 2-deoxy-2-[18 F]fluorosorbitol using sodium borohydride on aluminum oxide.

    Koki Hasegawa, Kazuhiro Koshino, Takahiro Higuchi

    Journal of labelled compounds & radiopharmaceuticals ,  64 (1) 40 - 46 ,  2021.01

    Multiple Authorship ,  ISBN: 0362-4803

    DOI PubMed

  • Rationale for Translational Research on Targeted Alpha Therapy in Japan —Renaissance of Radiopharmaceuticals Utilizing Astatine-211 and Actinium-225—

    Tsuneo Yano, Koki Hasegawa, Tatsuhiko Sato, Mitsuaki Tatsumi, Tadashi Watabe, Yuichiro Kadonaga, Kazuya Kabayama, Koichi Fukase, Akiko Hachisuka, Yoko Hirabayashi, Hirofumi Fujii, Yoshiharu Yonekura

    RADIOISOTOPES ,  69 (10) 329 - 340 ,  2020.10

    Multiple Authorship ,  ISBN: 1884-4111

    DOI

  • Enhancement of direct membrane penetration of arginine-rich peptides by polyproline II helix structure.

    Takashi Ohgita, Yuki Takechi-Haraya, Keisuke Okada, Saki Matsui, Misaki Takeuchi, Chihiro Saito, Kazuchika Nishitsuji, Kenji Uchimura, Ryuji Kawano, Koki Hasegawa, Kumiko Sakai-Kato, Kenichi Akaji, Ken-Ichi Izutsu, Hiroyuki Saito

    Biochimica et biophysica acta. Biomembranes ,  1862 (10) 183403 - 183403 ,  2020.10

    Multiple Authorship

    DOI PubMed

display all >>

Books 【 display / non-display

  • Handbook of in vivo chemistry in mice : from lab to living system

    Tanaka, Katsunori, Vong, Kenward

    Wiley-VCH ,  2020 ,  ISBN: 9783527344321

Joint Research activities 【 display / non-display

  • Signal molecules of ASCL1, a lineage-specific transcription factor for small cell carcinoma of the lung

    Collaboration in Japan  

    Project Year:2020.04 - 2024.03 

  • Development of a method to predict prognosis and treatment effect based on estrogen receptor expression level

    Collaboration in Japan  

    Project Year:2017.04 - 2020.03 

    It is difficult to produce good quality antibodies. Occasionally, the reproducibility of an experiment may not be achieved due to the quality of the antibody. To overcome these problems, we prepared low molecular-weighted ligand agents that can be constant quality for detection. The method using low molecular-weighted ligand agents alternative to antibodies was named Western ligand blot and ligand derivertive stain, respectively. In this study, tamoxifen derivative was used to detect estrogen receptor. The estrogen receptor was successfully detected by the Western ligand blot. We have also successfully stained pathological sections of lung adenocarcinoma and lung squamous cell carcinoma with ligand derivaertive stain.

  • Regulation of small cell lung carcinoma cells by interference between axon guidance molecules and their receptors

    Collaboration in Japan  

    Project Year:2016.04 - 2018.03 

    ,  Member: MATSUO Akira, SHINMYO Yohei, HASEGAWA Koki

    The axon guidance molecule-receptor system works not only in neural network formation, and but also in cancer cell proliferation and apoptosis. Draxin and Netrin1 share their receipt, DCC and Neogenin. This study was done to elucidate the significance of the guidance molecule-receptor system in lung cancer cell proliferation and survival. Western blotting and immunohistochemical studies revealed that small cell lung cancer and non-small cell lung cancer express these molecules. Though gene knockdown and over-expression studies using small cell lung cancer cell lines, using non-small cell lung cancer cell lines, we demonstrated that the system works in lung cancer cell proliferation and survival. And, it is suggested that Draxin could interact directly with Netrin1 in cancer cell proliferation.

  • Relationship between receptor expression revaled by rhodamine-labeled peptides and calcium responses in cortical neurons

    Collaboration in Japan  

    Project Year:2016.04 - 2018.03 

    Neural responses to a ligand exhibit a wide variation from neuron to neuron, however, underling mechanisms of the response variation remains unclear. One possible mechanism is a variation of the number of receptors expressed in each neural membrane. To examine this hypothesis, we synthesized rhodamine-labeled orexin A compound, which enabled us to quantify the amount of orexin binding to orexin receptors, OX1 and OX2. Application of rhodamine-labeled orexin A to the cortical surface heterogeneously increased both the intensity of the rhodamine fluorescence and [Ca2+]i. We classified neurons into high- and low-responding neurons based on the peak amplitude of [Ca2+]i increase. Intensity of the rhodamine fluorescence in high-responding neurons was significantly larger than that in low-responding neurons. These results suggest that a part of mechanisms for varying neural responses including [Ca2+]i increases are the diversity of the amount of receptor expression in the neural membrane.

  • Development of multimodal theranostics tracer for personalized medicine in immuno-oncology

    Collaboration in Japan  

    Project Year:2015.04 - 2018.03 

    ,  Member: NAKAMURA Michihiro, HASEGAWA Koki

    In this study, multimodal theranostics tracer using nano particle has been developed to use for diagnostication with CT, MRI, SPECT, PET, and also treatment with unsealed source radiotherapy in immuno-oncology. The methods for labeling antibody and radioisotope to the organosilica nanoparticle that contained fluorescent dye were developed. The differences of the pharmacokinetics of the tracer in the mice that had transplanted different type of the tumor cell were observed. It was indicated that antibody imaging has been succeeded using this developed method. In spite of this observation, wholebody imaging using SPECT and fluorecent imaging were not succeeded due to low sensitivity. Additional technical development for higher sensitivity will be required to apply this tracer for clinical use in the future.

display all >>